Skip to main content
placeholder image

Evidence for lithium in bipolar prophylaxis

Conference Paper


Abstract


  • Lithium remains as the unanimous first-line choice for the maintenance treatment of bipolar disorder ever since the first efficacy trial of Lithium prophylaxis in recurrent mood disorders in 1967.However, because of illness factors such as predominance of depression, tolerability profile, patient preference, and treatment resistance, many patients are prescribed an alternative. This presentation highlights available research evidence concerning the efficacy and effectiveness of

    lithium prophylaxis in bipolar disorder. The impact of lithium prophylaxis is likely to be less significant on the atypical and comorbid cases of bipolar disorder, increasingly seen in clinical practice, than it is on typical cases of BPD, but the

    superiority of other medications over lithium in the long-term treatment of those atypical or comorbid cases is at present

    not convincingly proved by research. It is well established that lithium discontinuation is associated with increased risk of mood episode recurrence in the following months in addition to rapid reduction in time to recurrence when lithium is abruptly discontinued. Clinicians need a greater understanding of the origins of necessary beliefs and concerns about lithium, which can predict and enhance not only not only address enhancing adherence but also can explain why adherence status changes over time.

Publication Date


  • 2018

Citation


  • Pai, N. B. (2018). Evidence for lithium in bipolar prophylaxis. WFSBP 2018 (pp. 90-90).

Start Page


  • 90

End Page


  • 90

Abstract


  • Lithium remains as the unanimous first-line choice for the maintenance treatment of bipolar disorder ever since the first efficacy trial of Lithium prophylaxis in recurrent mood disorders in 1967.However, because of illness factors such as predominance of depression, tolerability profile, patient preference, and treatment resistance, many patients are prescribed an alternative. This presentation highlights available research evidence concerning the efficacy and effectiveness of

    lithium prophylaxis in bipolar disorder. The impact of lithium prophylaxis is likely to be less significant on the atypical and comorbid cases of bipolar disorder, increasingly seen in clinical practice, than it is on typical cases of BPD, but the

    superiority of other medications over lithium in the long-term treatment of those atypical or comorbid cases is at present

    not convincingly proved by research. It is well established that lithium discontinuation is associated with increased risk of mood episode recurrence in the following months in addition to rapid reduction in time to recurrence when lithium is abruptly discontinued. Clinicians need a greater understanding of the origins of necessary beliefs and concerns about lithium, which can predict and enhance not only not only address enhancing adherence but also can explain why adherence status changes over time.

Publication Date


  • 2018

Citation


  • Pai, N. B. (2018). Evidence for lithium in bipolar prophylaxis. WFSBP 2018 (pp. 90-90).

Start Page


  • 90

End Page


  • 90